PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Compound X – an inhaled β2 agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Modulation of transient receptor potential vanilloid-1 (TRPV1) by inhaled prostaglandin-E2 (PGE2) and bradykinin (BK) is associated with increased cough sensitivity to capsaicin (CPS) and autonomic dysregulation of cardiac rhythm in healthy subjects Source: Virtual Congress 2020 – Occupational and environmental causes of respiratory disease Year: 2020
Airway responsiveness to capsaicin (C), but not to methacholine (M), is influenced by gastric acid secretion inhibition Source: Eur Respir J 2005; 26: Suppl. 49, 278s Year: 2005
Differences in bronchoprotective subsensitivity between formoterol (FM) and salmeterol (SM) are associated with β2 -adrenoceptor polymorphism Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002
Inhibitory activity of fluticasone propionate (FP) and salmeterol (SAL) on TGF-β–induced expression of α-smooth muscle actin (α-SMA) by human primary airway fibroblasts (Fbs) Source: Annual Congress 2003 - Cell signalling and cytokines in asthma Year: 2003
Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD) Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Development of bronchospasm in normal and sensitized rabbits: exogenous administration vs. endogenous liberation of constrictor agonists Source: Eur Respir J 2005; 26: Suppl. 49, 365s Year: 2005
Bronchodilation by deep inhalation (DI) during exercise induced bronchoconstriction (EIB) in children Source: Eur Respir J 2002; 20: Suppl. 38, 225s Year: 2002
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Airway responsiveness to methacholine (Mch), adenosine 5- monophosphate (AMP), mannitol (Man), eucapnic voluntary hyperpnea (EVH) and a sport-specific field exercise challenge (Ex) in cross country ski athletes Source: Eur Respir J 2002; 20: Suppl. 38, 410s Year: 2002
Relation between the acute response to salbutamol and long-term FEV1 responses to tiotropium (TIO), formoterol (FORM) and its combination (T+F) in COPD patients Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
The inhaled anticholinergic agent, aclidinium bromide, reverses cholinergic-induced bronchoconstriction in guinea pigs with a fast onset of action and a long duration of effect Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Effect of adenosine 5´-triphosphate (ATP) challenge vs. adenosine 5´-monophosphate (AMP) on the threshold of capsaicin-induced cough in healthy non-smokers, current smokers and patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 708s Year: 2004
The response to methacholine (Mch) bronchoprovocation in the absence of deep inspiration (DI) is dependent on airway smooth muscle (ASM) content Source: Eur Respir J 2004; 24: Suppl. 48, 661s Year: 2004